MEI Pharma Files Standard 8-K Report

TL;DR

**MEI Pharma filed a standard 8-K, but the filing itself doesn't reveal any new material info.**

AI Summary

MEI Pharma, Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 20, 2024. The filing is a standard current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating no specific material financial or operational changes were disclosed beyond the filing itself. The company, based in San Diego, California, with IRS Employer Identification No. 51-0407811, operates in the pharmaceutical preparations industry.

Why It Matters

This filing is a routine disclosure, indicating MEI Pharma is maintaining its regulatory compliance. Without specific details on the 'Other Events' mentioned, its immediate impact on investors is minimal.

Risk Assessment

Risk Level: low — The filing is a routine regulatory update without disclosing any specific material events that would introduce new risks.

Key Players & Entities

• MEI Pharma, Inc. (company) — Registrant
• February 20, 2024 (date) — Date of earliest event reported
• February 21, 2024 (date) — Filing date
• 51-0407811 (dollar_amount) — IRS Employer Identification No.
• San Diego, California (company) — Principal Executive Offices location

FAQ

Key Financial Figures

• $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar
• $25,000,000 — from time to time, at its option, up to $25,000,000 in aggregate principal amount of an ind
• $75.0 m — Company's public float being less than $75.0 million, and in accordance with the terms
• $10,300,000 — an aggregate gross sales price of up to $10,300,000. If the Company's public float increase
• $100,000,000 — ruary 20, 2024 for an offering of up to $100,000,000 of various securities, including shares

Filing Documents

• meip-20240221.htm (8-K) — 44KB
• meip-ex1_1.htm (EX-1.1) — 287KB
• 0000950170-24-017875.txt ( ) — 488KB
• meip-20240221.xsd (EX-101.SCH) — 23KB
• meip-20240221_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events On February 20, 2024, MEI Pharma, Inc. (the "Company"), entered into a Capital on Demand Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC (the "Agent"), pursuant to which the Company may sell, from time to time, at its option, up to $25,000,000 in aggregate principal amount of an indeterminate amount of shares (the "Shares") of the Company's common stock, par value $0.00000002 per share, through the Agent, as the Company's sales agent. However, due to the offering limitations applicable to the Company under General Instruction I.B.6. of Form S-3 as a result of the Company's public float being less than $75.0 million, and in accordance with the terms of the Sales Agreement, the Company will initially be offering Shares having an aggregate gross sales price of up to $10,300,000. If the Company's public float increases such that it may sell additional amounts under the Sales Agreement and the Registration Statement (as defined below), the Company may file supplements to the prospectus included in the Registration Statement prior to making additional sales. Any Shares to be offered and sold under the Sales Agreement will be issued and sold (i) by methods deemed to be an "at-the-market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or in negotiated transactions, if authorized by the Company, and (ii) pursuant to, and only upon the effectiveness of, a Registration Statement on Form S-3 filed by the Company with the Securities and Exchange Commission on February 20, 2024 for an offering of up to $100,000,000 of various securities, including shares of the Company's common stock, preferred stock, warrants, rights and/or units for sale to the public in one or more public offerings (the "Registration Statement").

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 Sales Agreement by and between MEI Pharma, Inc. and JonesTrading Institutional Services LLC, dated as of February 20, 2024. 104 Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI PHARMA, INC. Date: February 21, 2024 By: /s/ Justin J. File Justin J. File Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR